CLDN6 Recombinant Monoclonal Antibody

Claudin-6 is a tight junction protein that has emerged as a compelling target in cancer research and developmental biology due to its highly restricted expression pattern in adult tissues combined with frequent overexpression in various malignancies. This oncofetal antigen plays critical roles in epithelial barrier formation and cell-cell adhesion, making it particularly relevant for researchers investigating tumor biology, stem cell differentiation, and signal transduction pathways.

This recombinant monoclonal antibody against human CLDN6, clone 6D4, offers the reproducibility and consistency that demanding experimental workflows require. Produced using recombinant technology with a defined sequence, this antibody eliminates the lot-to-lot variability that can compromise longitudinal studies or multi-site collaborations. The human IgG1 isotype format provides flexibility for researchers working with flow cytometry applications where Fc-mediated detection is advantageous.

Functional validation demonstrates robust performance across multiple platforms. In ELISA-based binding assays, the antibody exhibits high-affinity interaction with immobilized human CLDN6 protein, achieving EC50 values in the low nanogram per milliliter range. Flow cytometry validation confirms specific detection of CLDN6-expressing cells, with clear discrimination between transfected and untransfected populations demonstrated in both HEK-293T and MC38 cell lines engineered to stably express human CLDN6. These validation studies employed antibody concentrations of 2 µg per million cells, providing a practical starting point for optimization in your own experimental system.

Whether you are characterizing CLDN6 as a potential therapeutic target, investigating tight junction biology in developmental contexts, or exploring its role in stem cell populations, this affinity-purified antibody delivers the specificity and batch consistency essential for generating reliable, publishable data.